Pooled safety analysis from two phase III studies of secukinumab in paediatric patients with moderate-to-severe plaque psoriasis up to week 52
Sticherling M, Nikkels AF, Hamza AM, Kwong P, Ortmann CE, Papanastasiou P, Forrer P, Keefe D (2022)
Publication Type: Conference contribution
Publication year: 2022
Journal
Publisher: WILEY
City/Town: HOBOKEN
Pages Range: E39-E40
Conference Proceedings Title: BRITISH JOURNAL OF DERMATOLOGY
Authors with CRIS profile
Involved external institutions
University of Liège (ULg) / Université de Liège
Belgium (BE)
Alexandria University / جامعة الإسكندرية
Egypt (EG)
Solutions Through Advanced Research
United States (USA) (US)
Novartis AG
Switzerland (CH)
Belgium (BE)
Alexandria University / جامعة الإسكندرية
Egypt (EG)
Solutions Through Advanced Research
United States (USA) (US)
Novartis AG
Switzerland (CH)
How to cite
APA:
Sticherling, M., Nikkels, A.F., Hamza, A.M., Kwong, P., Ortmann, C.-E., Papanastasiou, P.,... Keefe, D. (2022). Pooled safety analysis from two phase III studies of secukinumab in paediatric patients with moderate-to-severe plaque psoriasis up to week 52. In BRITISH JOURNAL OF DERMATOLOGY (pp. E39-E40). HOBOKEN: WILEY.
MLA:
Sticherling, Michael, et al. "Pooled safety analysis from two phase III studies of secukinumab in paediatric patients with moderate-to-severe plaque psoriasis up to week 52." Proceedings of the BRITISH JOURNAL OF DERMATOLOGY HOBOKEN: WILEY, 2022. E39-E40.
BibTeX: Download